retatrutide ly3437943 clinical trial results produces up to 30.3% weight loss in Phase 3 Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon

"Use of GLP-1 [drugs] is rapidly expanding in this population, highlighting an important area for future research." More information The Mayo Clinic has more on GERD

How should I prepare for my first consultation with an Aetna nutritionist

One of the most common side effects people experience on these medications is nausea

Our smoothies are more than just a delicious treatthey're a power packed meal on-the-go to help our guests stay on track with their goals, said Wan Kim, CEO of Smoothie King

In a 12-week human trial, participants achieved on average

Schedule your consultation today and explore how nutrient-infused support can enhance your progress, energy, and long-term results